New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc

Nov 4, 2026

Strategic Roche Diagnostics Partnership, New Biomarker Findings and Expanding Clinical Research Could Help Transform Patient Selection for Non-Small Cell Lung Cancer Treatment, While Genprex, Inc. (N A S D A Q: GNPX) Advances Additional Opportunities in Small Cell Lung Cancer and Diabetes Gene Therapy.

AUSTIN, Texas - Nov. 4, 2026 - PRLog -- Genprex, Inc. (N A S D A Q: GNPX) $GNPX is generating renewed attention across the biotechnology sector with another important research development involving its lead investigational gene therapy, REQORSA®. The company announced November 4 that new research has identified TROP2 expression as a potential predictive biomarker for response to REQORSA, adding another important dimension to its developing precision-medicine strategy for lung cancer.

The announcement is particularly encouraging because researchers identified a relationship between TROP2 expression and treatment sensitivity across multiple preclinical models of non-small cell lung cancer (NSCLC). The findings were further supported by an analysis of pretreatment tumor biopsies from patients enrolled in a clinical trial evaluating REQORSA.

For Genprex, this represents an important opportunity to build upon its existing clinical research and investigate how biomarker testing could help identify patients most likely to benefit from treatment. The company is working toward a more personalized approach to cancer therapy, an area receiving increasing attention throughout the oncology industry.

The new research is scheduled to be presented November 18–20 at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

New TROP2 Findings Add Momentum to REQORSA

The November 4 announcement highlights the potential importance of TROP2 expression in determining sensitivity to REQORSA.

Researchers found that low TROP2 expression was consistently associated with primary resistance to REQORSA across multiple preclinical NSCLC models. Analysis of pretreatment tumor biopsies from clinical-trial participants provided additional support for these observations.

The findings are important because biomarkers may help researchers better understand why certain patients respond differently to cancer treatments.

If additional research confirms these relationships, TROP2 testing could become an important component of patient selection for future REQORSA clinical studies.

Genprex is also investigating PTEN, another important biomarker associated with treatment response. Together, these research efforts demonstrate the company's interest in combining innovative gene therapy with more targeted approaches to cancer treatment.

Roche Diagnostics Collaboration: A Significant Strategic Relationship

One of Genprex's most important developments this year is its collaboration with Roche Diagnostics, announced August 3.

The partnership focuses on validating biomarker assays designed to help identify appropriate patients for Genprex's NSCLC clinical program.

Roche brings extensive diagnostic expertise to the collaboration, while Genprex contributes its developing gene therapy platform and growing body of biomarker research.

The initial work centers on two important biomarkers:
  • TROP2: Being investigated for its potential ability to identify patients more likely to respond to REQORSA.
  • PTEN: A tumor-suppressor protein whose expression has also demonstrated an association with treatment response in previous research.

Roche Diagnostics will conduct assay validation using its TROP2 antibody. Genprex anticipated completion of these studies around the end of 2026, with potential integration into its NSCLC clinical program following successful validation.

This collaboration is especially noteworthy because it connects Genprex with an established global diagnostics organization while advancing a more sophisticated patient-selection strategy.

The ultimate objective is to better identify patients who may benefit from REQORSA and potentially improve the precision of future clinical studies.

REQORSA: Advancing an Innovative Approach to Lung Cancer

At the center of Genprex's oncology strategy is REQORSA, also known as quaratusugene ozeplasmid.

The investigational gene therapy is designed to deliver the TUSC2 tumor-suppressor gene into cancer cells using Genprex's proprietary ONCOPREX Delivery System, which utilizes lipid-based nanoparticles.

TUSC2 is frequently reduced or absent in several forms of lung cancer. REQORSA is designed to restore tumor-suppressor activity and influence multiple biological pathways involved in cancer progression.

Genprex is investigating REQORSA through its Acclaim clinical development program.

Acclaim-1 evaluates REQORSA in combination with AstraZeneca's Tagrisso in patients with advanced NSCLC carrying specific EGFR mutations.

Acclaim-3 evaluates REQORSA in an extensive-stage small cell lung cancer treatment strategy.

Both programs represent important components of the company's longer-term oncology ambitions. The programs have received FDA Fast Track designations, and the small cell lung cancer program has also received Orphan Drug Designation.

These designations provide important regulatory development pathways as Genprex continues its clinical research.

TUSC2 Research Creates Additional Scientific Interest

Genprex is also expanding its scientific investigation of TUSC2 through its sponsored research collaboration with Meharry Medical College.

On November 4, research titled "TUSC2 Gene Therapy in Humans Induces a Cellular-Resilience Program" is scheduled for presentation at the Gerontological Society of America's 2026 Annual Scientific Meeting.

The research explores TUSC2's relationship with mitochondrial biology, cellular resilience and biological processes associated with aging.

This follows an October 21 peer-reviewed publication examining TUSC2's role in maintaining cellular function during brain aging.

These developments add another dimension to the company's scientific platform by examining the broader biological functions of the gene central to REQORSA.

While additional research is necessary to establish any potential therapeutic applications beyond oncology, the work demonstrates continued scientific interest in TUSC2.

Diabetes Gene Therapy Adds Another Development Opportunity

Beyond cancer, Genprex is pursuing an additional opportunity through its diabetes gene therapy program.

The company's approach uses AAV technology to deliver Pdx1 and MafA genes to the pancreas, with the objective of restoring insulin-producing cell function.

Preclinical studies have produced encouraging findings in Type 1 and Type 2 diabetes models, including improvements in glucose control and insulin-related measures.

On August 18, Genprex announced the selection of a U.S.-based contract development and manufacturing organization to begin manufacturing scale-up for its diabetes gene therapy candidate.

This represents an important development as the company works toward preparing the program for future clinical studies.

Having separate development programs targeting cancer and diabetes gives Genprex multiple areas of potential therapeutic opportunity.

Looking Ahead: Important Catalysts for $GNPX Investors

Genprex has several meaningful milestones approaching:
  • November 18–20: Presentation of new TROP2 biomarker research in Barcelona.
  • Late 2026: Anticipated completion of Roche Diagnostics biomarker assay validation.
  • Continued advancement of the Acclaim oncology clinical programs.
  • Additional TUSC2 research and scientific collaboration developments.
  • Continued manufacturing scale-up for the diabetes gene therapy program.

Genprex Is Building an Intriguing Gene Therapy Story

Genprex brings together several important areas of biotechnology innovation: precision lung cancer treatment, gene therapy, biomarker-guided patient selection and diabetes research.

The latest TROP2 findings add another important piece to the REQORSA development story, while the Roche Diagnostics collaboration provides a valuable strategic relationship as the company works toward more personalized cancer treatment approaches.

With additional scientific presentations ahead, continued clinical development and a second therapeutic program targeting diabetes, Genprex has multiple opportunities to demonstrate further progress.

For investors following emerging biotechnology companies, GNPX presents an evolving story centered on innovative science, strategic collaboration and the pursuit of potentially important new treatment options. The coming months could be especially meaningful as Genprex works to translate its expanding research foundation into further clinical development milestones.

For more information on $GNPX visit: www.genprex.com and https://compasslivemedia.com/gnpx/

Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: [email protected]
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website

Contact
CorporateAds
***@gmail.com

Photos: (Click photo to enlarge)




Source: CorporateAds

Read Full Story - New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc | More news from this source

Press release distribution by PRLog
MORE NEWS
Alexis Badel produces another Happy Valley masterclass with a brilliant treble
Nov 11, 2026
Alexis Badel produces another Happy Valley masterclass with a brilliant treble

Alexis Badel continued his sensational form at Happy Valley with a treble on Wednesday night, with his successful mid-race move aboard consistent galloper Pope Cody the highlight. The French jockey booted home Ricky Yiu Poon-fai’s Lovely Miles and the Douglas Whyte-trained Cheerful Wongchoy before sealing his three-timer with a smart ride aboard Pope Cody in the Class Three Fung Mo Handicap (1,800m). “It’s good. I think I’ve had some good rides – some good draws, some bad draws – but we were...

‘True great’ Harry Kane set to break appearance record as he inspires new England generation
Nov 11, 2026
‘True great’ Harry Kane set to break appearance record as he inspires new England generation

England captain Harry Kane is set to cap his golden year by breaking the Three Lions’ appearance record in Thursday’s Nations League clash with Croatia. When Kane leads his national team out at Wembley to earn his 126th cap, he will surpass the previous record held by former England goalkeeper Peter Shilton since 1990. It will be the latest landmark moment in an incredible 12 months for the Bayern Munich striker, who became the first English player in 25 years to win the Ballon d’Or in...

Jon Rahm says ‘stop blaming LIV’ for his majors form as failed league files bankruptcy plan
Nov 11, 2026
Jon Rahm says ‘stop blaming LIV’ for his majors form as failed league files bankruptcy plan

Jon Rahm has insisted that his three-year stay with LIV Golf was not the reason for ⁠a drop-off in his performance at ⁠golf’s major championships. Rahm, who is leaving ⁠behind LIV to play a full DP World Tour schedule in 2027, said he was tired of what some media members “insinuate” was a connection between playing a lighter, less competitive schedule and being less prepared for the majors. LIV is set to wind down operations after plans to ‌come out of bankruptcy with a so-called “LIV 2.0” model...

Judy Murray on brutal reality of raising stars, says Venus Williams deserved Hong Kong spot
Nov 11, 2026
Judy Murray on brutal reality of raising stars, says Venus Williams deserved Hong Kong spot

Hong Kong prospect Kai Thompson has been told to brace himself for a bruising introduction to professional tennis, but that the short-term pain could result in long-term gain. Judy Murray, whose sons, Andy and Jamie, both won multiple grand slams and ascended to world No 1 in singles and doubles respectively, also encouraged the 18-year-old Thompson’s parents to “learn as much as possible about what tennis will demand from him and his body over the next two years”. Speaking to the South China...

Chinese table tennis star Wang Chuqin admits he is in ‘slump’, pledges to regain peak form
Nov 10, 2026
Chinese table tennis star Wang Chuqin admits he is in ‘slump’, pledges to regain peak form

Chinese table tennis star Wang Chuqin has acknowledged he is in a “slump”, taking to social media after exiting the WTT Champions Frankfurt in the round of 16 following a 36-day rest and adjustment period. The tournament, which concluded on Sunday with Japan sweeping both singles titles for a second consecutive edition, marked China’s worst Champions-tier result this year, with none of the mainland’s nine entrants reaching the semi-finals. China claimed just one title across six WTT Champions...

SCMP Best Bets: Master Phoenix can soar at Happy Valley
Nov 10, 2026
SCMP Best Bets: Master Phoenix can soar at Happy Valley

Jay Rooney LEADING AGILITY - R7 (5) Very strong win last start at the Valley and can repeat the dose here   Owen Goulding MASTER PHOENIX - R3 (11) Hugely unlucky when hampered last start and draws much better tonight   Paul Lally GOLDEN ACE - R5 (4) Has shown plenty of ability and should appreciate the step up in distance   Phillip Woo COUNTRY PRIDE - R6 (7) Has run well in his first three starts this term and does finally draw a gate   Trackwork Spy CLOUD NINE - R6 (4) Near misses on both...

Horse dies after Sha Tin training fall that sends jockey Angus Chung to hospital
Nov 10, 2026
Horse dies after Sha Tin training fall that sends jockey Angus Chung to hospital

Hong Kong jockey Angus Chung Yik-lai faces up to six weeks on the sidelines following a nasty fall on Tuesday, that killed the Tony Cruz-trained United Hua Steed. The three-year-old horse stumbled during morning barrier trials at Sha Tin, sending Chung crashing to the dirt while suffering a fatal injury as a result. While Chung was rushed to hospital, and was later diagnosed with a concussion, fractured ribs and a broken nose, United Hua Steed could not be saved, and the Hong Kong Jockey Club...

Harry Bentley optimistic about Packing Angel and Hymnbook’s chances at Happy Valley
Nov 10, 2026
Harry Bentley optimistic about Packing Angel and Hymnbook’s chances at Happy Valley

Harry Bentley is upbeat about his prospects of another win at Happy Valley on Wednesday night, with the British jockey rating Packing Angel and Hymnbook strong chances in their respective races. Fresh from an upset win on $38.9 outsider Thriving Brothers at Sha Tin on Sunday, Bentley will bid to add to his seasonal haul of five victories with five rides at the city circuit. He reunites with Packing Angel in the Class Two Lung Cheung Handicap (1,650m) after guiding the Francis Lui Kin-wai-trained...

Chengdu Rongcheng fire coach Aloisi after incredible Chinese Super League title choke
Nov 10, 2026
Chengdu Rongcheng fire coach Aloisi after incredible Chinese Super League title choke

Australian coach John Aloisi has been ⁠sacked as ⁠coach of Chengdu Rongcheng ⁠after his team squandered a huge lead at the top of the table to miss out on the Chinese Super League title at the weekend. Chengdu lost their last ‌four matches to give up a lead which once stood at 12 points, allowing Dalian Yingbo to overhaul them and claim a first CSL title after a 3-1 win over Tianjin Tiger on Sunday. “Mr John Aloisi will no longer ⁠serve as head coach of Chengdu Rongcheng Football Club, and his...

Hong Kong fencer Harris Ho makes Youth Olympic Games history with foil gold in Dakar
Nov 10, 2026
Hong Kong fencer Harris Ho makes Youth Olympic Games history with foil gold in Dakar

Making history is becoming something of a habit for Hong Kong’s Harris Ho Shing-him, who has claimed the city’s first fencing gold at a Youth Olympic Games. A member of the men’s foil team that claimed a rare silver medal at the Asian Games, the 17-year-old sealed his individual foil title in Dakar on Monday, despite losing his first bout of the day. Ho overcame a 5-2 defeat at the hands of Aris Kiayias in his opening match in Pool 1, eventually turning the tables on his Cypriot rival in the...

Infantino’s re-election as Fifa boss a ‘foregone conclusion’, says Asian football official
Nov 10, 2026
Infantino’s re-election as Fifa boss a ‘foregone conclusion’, says Asian football official

Gianni Infantino’s re-election as president of Fifa is “a foregone conclusion”, Asian Football Confederation (AFC) vice-president Hashem Haidar said on Monday. Haidar, who is also president of the Lebanese Football Federation, said at the unveiling of a new Fifa Arena pitch in the village of Shanay near the town of Aley, east of Beirut, that “we fully and publicly support” the divisive head of the game’s global governing body. Infantino, who was in Lebanon for Monday’s event, faced stinging...

‘Bigger, better’ Blast Premier Rivals returns to Hong Kong, officials eye Asia expansion
Nov 10, 2026
‘Bigger, better’ Blast Premier Rivals returns to Hong Kong, officials eye Asia expansion

Blast Premier Rivals returns to Hong Kong “even bigger and better”, and officials hope the city acts as a bridge to mainland China and beyond in the coming years. The esports event, which will see eight of the world’s best CS2 squads compete for a share of a US$1million (HK$7,841,460) prize pool, sold out the AsiaWorld-Arena last year when descending on the city for the first time. It was Hong Kong’s first esports event to be awarded the “M” Mark for major events, with more than 30,000 fans...

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

SukanKini focuses on the nation’s favorite sports and local leagues and the rivalry between our teams with other players across South East Asia and even all over the world.